Is this you? Create Your Porfile
Avatar

Brian A. Kirk

Merck & Co.

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Brian A. Kirk is active.

Explore More

Publication

Featured researches published by Brian A. Kirk.

Bioorganic & Medicinal Chemistry Letters | 2002

Synthesis and Activity of Novel HIV Protease Inhibitors with Improved Potency Against Multiple PI-Resistant Viral Strains

Joseph L. Duffy; Nancy J. Kevin; Brian A. Kirk; Kevin T. Chapman; William A. Schleif; David B. Olsen; Mark Stahlhut; Carrie A. Rutkowski; Lawrence C. Kuo; Lixia Jin; Jiunn H. Lin; Emilio A. Emini; James R. Tata

Substitution of the t-butylcarboxamide substituent in analogues of the HIV protease inhibitor (PI) Indinavir with a trifluoroethylamide moiety confers greater potency against both the wild-type (NL4-3) virus and PI-resistant HIV. The trifluoroethyl substituent also affords a slower clearance rate in vivo (dogs); however, this may be due to more potent inhibition of at least two P450 isoforms.

Archive | 2005

Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes

Joseph L. Duffy; David E. Kaelin; Ann E. Weber; Brian A. Kirk

Bioorganic & Medicinal Chemistry Letters | 2005

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

Joseph L. Duffy; Brian A. Kirk; Zenon Konteatis; Elizabeth Louise Campbell; Rui Liang; Edward J. Brady; Mari R. Candelore; Victor D.-H. Ding; Guoqiang Jiang; Frank Xiaoqing Liu; Sajjad A. Qureshi; Richard Saperstein; Deborah Szalkowski; Sharon Tong; Lauri M. Tota; Dan Xie; Xiaodong Yang; Peter Zafian; Song Zheng; Kevin T. Chapman; Bei B. Zhang; James R. Tata

Bioorganic & Medicinal Chemistry Letters | 2007

4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.

Joseph L. Duffy; Brian A. Kirk; Liping Wang; George J. Eiermann; Huaibing He; Barbara Leiting; Kathryn A. Lyons; Reshma A. Patel; Sangita B. Patel; Alexsandr Petrov; Giovanna Scapin; Joseph K. Wu; Nancy A. Thornberry; Ann E. Weber

Archive | 2003

Cyanothiophene derivatives, compositions containing such compounds and methods of use

Joseph L. Duffy; Elizabeth Louise Campbell; Brian A. Kirk; Rui Liang; James R. Tata; Kevin T. Chapman; Zenon Konteatis

Bioorganic & Medicinal Chemistry | 2006

Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor

Sheila M. Cohen; Joseph L. Duffy; Corin O. Miller; Brian A. Kirk; Mari R. Candelore; Victor D.-H. Ding; Gregory J. Kaczorowski; Laurie Tota; Jeffrey G. Werrmann; Michael Wright; Emma R. Parmee; James R. Tata; Bei B. Zhang

Archive | 2000

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

James R. Tata; Kevin T. Chapman; Joseph L. Duffy; Nancy J. Kevin; Yuan Cheng; Thomas A. Rano; Fengqi Zhang; Tracy Huening; Brian A. Kirk; Zhijian Lu; Subharekha Raghavan; Fred J. Fleitz; Daniel E. Petrillo; Joseph D. Armstrong; Richard J. Varsolona; David Askin; R. Scott Hoerrner; Robert Purick

Archive | 2000

Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

James R. Tata; Kevin T. Chapman; Joseph L. Duffy; Nancy J. Kevin; Yuan Cheng; Thomas A. Rano; Fengqi Zhang; Tracy Huening; Brian A. Kirk; Zhijian Lu; Subharekha Raghavan; Fred J. Fleitz; Daniel E. Petrillo; Joseph D. Armstrong; Richard J. Varsolona; David Askin; R. Scott Hoerrner; Robert Purick

Bioorganic & Medicinal Chemistry Letters | 2003

Novel HIV-1 protease inhibitors active against multiple PI-Resistant viral strains: coadministration with indinavir

Nancy J. Kevin; Joseph L. Duffy; Brian A. Kirk; Kevin T. Chapman; William A. Schleif; David B. Olsen; Mark Stahlhut; Carrie A. Rutkowski; Lawrence C. Kuo; Lixia Jin; Jiunn H. Lin; Emilio A. Emini; James R. Tata

Bioorganic & Medicinal Chemistry Letters | 2003

HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent

Joseph L. Duffy; Brian A. Kirk; Nancy J. Kevin; Kevin T. Chapman; William A. Schleif; David B. Olsen; Mark Stahlhut; Carrie A. Rutkowski; Lawrence C. Kuo; Lixia Jin; Jiunn H. Lin; Emilio A. Emini; James R. Tata

Explore More

Collaboration

Dive into the Brian A. Kirk's collaboration.

Top Co-Authors
Avatar

Joseph L. Duffy

Merck

View shared research outputs
Top Co-Authors
Avatar

James R. Tata

Merck

View shared research outputs
Top Co-Authors
Avatar

Kevin T. Chapman

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors
Avatar

Nancy J. Kevin

Merck

View shared research outputs
Top Co-Authors
Avatar

Ann E. Weber

Merck

View shared research outputs
Top Co-Authors
Avatar

Daniel E. Petrillo

Merck

View shared research outputs
Top Co-Authors
Avatar

David Askin

Merck

View shared research outputs
Top Co-Authors
Avatar

Fred J. Fleitz

Merck

View shared research outputs
Top Co-Authors
Avatar

Joseph D. Armstrong

University of Virginia

View shared research outputs
Top Co-Authors
Avatar

R. Scott Hoerrner

Merck

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge